286 Background: Anti-PD-L1 immunotherapy has shown promising clinical activity in
urothelial carcinoma (UC). We report on a planned update of efficacy and follow-up in
patients (pts) receiving durvalumab for the treatment of locally advanced or metastatic UC.
Methods: Pts received durvalumab 10 mg/kg Q2W up to 12 months (mo), unacceptable
toxicity or confirmed progressive disease. Tumor PD-L1 expression was assessed using the
validated Ventana SP263 assay (PD-L1 high= TC≥ 25% or IC≥ 25%). Primary endpoints …

4525 Background: Anti-PD-L1 immunotherapy shows promising clinical activity in UC. We
report a planned update of the safety and efficacy of durvalumab in patients (pts) with locally
advanced/metastatic UC from a multicenter, phase 1/2 open-label study. Methods: Pts
received durvalumab 10 mg/kg every 2 weeks (Q2W) up to 12 months (mo) or until
unacceptable toxicity, progression, or starting another anticancer therapy. Primary endpoints
were safety and confirmed objective response rate (ORR) by blinded independent central …